

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A03/2017

DESPATCHED ON 28TH MARCH 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A2; B8, B13; Cw6, Cw7; DR7, DR17; DQ2, DQ-

				Summary of Results												
				PBL				T-Cells				B-Cells				
Total tested	9	10	10	10	19	21	20	21	19	19	19	19	19			
Positive	3	1	2	0	5	0	1	1	18	6	15	6	6			
Negative	6	9	8	10	14	21	19	20	1	13	4	13	13			
NT/Equivocal	1	0	0	0	2	0	1	0	3	3	3	3	3			
% Positive	33.3%	10.0%	20.0%	0.0%	26.3%	0.0%	5.0%	4.8%	94.7%	31.6%	78.9%	31.6%	31.6%			
% Negative	66.7%	90.0%	80.0%	100.0%	73.7%	100.0%	95.0%	95.2%	5.3%	68.4%	21.1%	68.4%	68.4%			
Consensus	Not Assessed	Negative	Negative	Negative	Not Assessed	Negative	Negative	Negative	Positive	Not Assessed	Positive	Not Assessed	Not Assessed			
HLA Antibody Specificity (Defined By CDC)	A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	A10 B16 DQ1			
				Without DTT				Without DTT				Without DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
9	YES	YES	YES	Positive	Negative	Positive	Negative	Positive	Negative	Equivocal	Negative	Positive	Negative	Positive	Negative	
11	YES	YES	YES	Equivocal	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
12	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	B-cell crossmatch uninterpretable due to poor cell viability
14		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
20	YES	YES	YES	Positive	Negative	Positive	Negative					Positive	Negative	Positive	Negative	Low cell viability in B cell prep. We would not report these results in a clinical situation
23		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
24		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
25		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
28		YES	YES					Weak Positive	Negative	Negative	Negative	NT	NT	NT	NT	B cells not reported due to positivity in negative control sera
34		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
35	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive					
38	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
39		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Too few B cells to report
41		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
42	YES	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
45		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
51		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
54		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
58		YES	YES					Equivocal	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
117	YES			Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative					
136		YES						Negative	Negative	Negative	Negative					
149	YES			Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative					
205	YES		YES	Negative	Positive	Negative	Negative					Negative	Positive	Negative	Negative	
212		YES	YES					NT	Negative	Negative	Negative	Positive	Negative	Negative	Negative	T lymphocyte in sera one could not be tested due to non-lymphocyte dead cell group
311		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
315		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A03/2017

DESPATCHED ON 28TH MARCH 2017

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	4	-	2	-	6	-	-	-	6	-	2	-	95	95	95
11	-	-	-	-	-	-	-	-	8	-	8	-	90	90	90
12	2	1	1	1	2	1	1	1	NT	NT	NT	NT	95	98	70
14					0	0	0	0	8	4	8	6		90	80
20	4	1	2	1					9	1	6	1	90		60
23					4	1	1	1	8	2	6	1		90	40
24					30	20	20	20	100	30	100	40		90	90
25					1	1	1	1	8	1	4	1		99	99
28					2	1	1	1	NT	NT	NT	NT		95	95
34					1	1	1	1	8	4	6	1		99	99
35	1	1	1	1	1	1	2	2					90	80	
38	4	1	1	1	2	1	1	1	6	1	1	1	95	80	70
39					-	-	-	-	NT	NT	NT	NT		97	
41					10	10	15	10	100	5	75	5		95	95
42	~10	<10	<10	<10					>80	~10	40-60	~10	95		95
45					1	1	1	1	8	4	8	8		95	90
51					4	0	0	0	8	0	8	8		90	80
54					10	0	0	0	100	30	90	60		99	99
58					10	5	5	5	100	50	5	80		95	95
117	1	1	1	1									87		
136					-	-	-	-						98	
149	-	-	-	-									80		
205	-	++++	-	-					-	++++	-	-	80		
212					NT	-	-	-	-	-	-	-		90	90
311					1	1	1	1	8	1	8	4		90	90
315					1	1	1	1	8	1	1	1		80	80

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A03/2017

DESPATCHED ON 28TH MARCH 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A2; B8, B13; Cw6, Cw7; DR7, DR17; DQ2, DQ-

				Summary of Results												
				PBL				T-Cells				B-Cells				
				7	8	8	8	16	18	17	18	18	18	18	18	
Total tested				3	1	1	0	4	0	0	0	17	1	11	1	
Positive				4	7	7	8	12	18	17	18	1	17	7	17	
Negative				2	1	1	1	3	1	2	1	3	3	3	3	
NT/Equivocal				42.9%	12.5%	12.5%	0.0%	25.0%	0.0%	0.0%	0.0%	94.4%	5.6%	61.1%	5.6%	
% Positive				57.1%	87.5%	87.5%	100.0%	75.0%	100.0%	100.0%	100.0%	5.6%	94.4%	38.9%	94.4%	
% Negative																
Consensus				Not Assessed	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Not Assessed	Negative	
HLA Antibody Specificity (Defined By CDC)				A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	
				With DTT				With DTT				With DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
9	YES	YES	YES	Positive	Negative	Positive	Negative	Positive	Negative	Equivocal	Negative	Positive	Negative	Positive	Negative	
11	YES	YES	YES	Equivocal	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
12	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	B cell crossmatch uninterpretable due to poor cell viability
14		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
15		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
20	YES		YES	Positive	Negative	Negative	Negative					Positive	Negative	Negative	Negative	
24		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
25		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
28		YES	YES					Weak Positive	Negative	Negative	Negative	NT	NT	NT	NT	B cell not reported due to positivity in negative control sera
34		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
35	YES	YES	YES	Equivocal	Equivocal	Equivocal	Equivocal	Equivocal	Equivocal	Equivocal	Equivocal					Samples failed DTT testing
38	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
39		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Too few B cells to report
41		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
42	YES		YES	Negative	Negative	Negative	Negative					Positive	Negative	Positive	Negative	
45		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
51		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
58		YES	YES					Equivocal	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
149	YES			Negative	Negative	Negative	Negative									
205	YES		YES	Negative	Positive	Negative	Negative					Negative	Positive	Negative	Negative	
212		YES	YES					NT	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
311		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
315		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A03/2017

DESPATCHED ON 28TH MARCH 2017

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	4	-	2	-	6	-	-	-	6	-	2	-	95	95	95
11	-	-	-	-	-	-	-	-	8	-	8	-	90	90	90
12	2	1	1	1	2	1	1	1	NT	NT	NT	NT	95	98	70
14					0	0	0	0	8	0	6	0		90	80
15					0	0	0	0	6	0	0	0		95	70
20	2	1	1	1					8	1	1	1	90		60
24					20	20	20	20	100	20	90	30		90	90
25					1	1	1	1	8	1	1	1		99	99
28					2	1	1	1	NT	NT	NT	NT		95	95
34					1	1	1	1	8	1	6	1		99	99
35	NT	NT	NT	NT	NT	NT	NT	NT					90	80	
38	4	1	1	1	2	1	1	1	6	1	1	1	95	80	70
39					-	-	-	-	NT	NT	NT	NT		97	
41					15	15	15	15	100	5	75	5		95	95
42	~10	<10	<10	<10					>80	<10	40-60	<10	95		95
45					1	1	1	1	6	1	8	8		95	90
51					2-4	0	0	0	8	0	6	0		90	80
58					10	5	5	5	100	5	90	5		95	95
149	-	-	-	-									80		
205	-	++++	-	-					-	++++	-	-	80		80
212					NT	-	-	-	-	-	-	-		90	90
311					1	1	1	1	8	1	8	1		90	90
315					1	1	1	1	8	1	1	1		80	80